Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 1;1(2):79-88.
doi: 10.1007/s40495-014-0009-3.

MicroRNA Regulating Glutathione S-Transferase P1 in Prostate Cancer

Savita Singh  1 , Girish C Shukla  1 , Sanjay Gupta  2
Affiliations

MicroRNA Regulating Glutathione S-Transferase P1 in Prostate Cancer

Savita Singh et al. Curr Pharmacol Rep. .

Abstract

Glutathione S-transferase P1 (GSTP1), an enzyme involved in detoxification process, is frequently inactivated in prostate cancer due to epigenetic modifications. Through in silico analysis we identified a subset of miRNAs that are putative targets in regulating GSTP1. miRNAs are small endogenous non-coding RNA that are critical regulators of various physiologic and pathologic processes and their level of expression may play a precise role in early diagnosis and prognosis of cancer. These small molecules have been detected in a wide variety of human biological specimens including blood, serum, urine, ejaculate and tissues, which could be utilized as clinically useful biomarker in early detection and prognosis of prostate cancer. The chapter summarizes the current knowledge about miRNA involved in GSTP1 regulation in prostate cancer and their potential as useful biomarkers of disease for early detection and prognosis, along with challenges and limitations in this development.

Keywords: GSTP1; epigenetics; miRNA; oxidative DNA damage; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Savita Singh, Girish C Shukla, and Sanjay Gupta declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of miR-133-a/b, miR-153-1/2, miR-590-3P/5P and miR-144/144* target sites on GSTP1 3′UTR.
See this image and copyright information in PMC

References

    1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71. - PubMed
    1. American Cancer Society. 2014 at the web at: http://www.cancer.org.
    1. Schröder FH, Roobol MJ. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol. 2009;19:227–31. - PubMed
    1. Catalona WJ, Loeb S. Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values. J Natl Compr Canc Netw. 2010;8:265–70. - PMC - PubMed
    1. Canby-Hagino E, Hernandez J, Brand TC, Troyer DA, Higgins B, Ankerst DP, Thompson IM, Leach RJ, Parekh DJ. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology. 2007;70:748–52. - PubMed

LinkOut - more resources